FCH
IMDX

Freestone Capital Holdings’s Insight Molecular Diagnostics IMDX Stock Holding History

Freestone Capital Holdings’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$3.54K – 405
2023
Q1 		$3.54K Hold
500
– – ﹤0.01% 373
2022
Q4 		$3.21K Hold
500
– – ﹤0.01% 380
2022
Q3 		$7K Hold
500
– – ﹤0.01% 375
2022
Q2 		$9K Hold
500
– – ﹤0.01% 418
2022
Q1 		$15K Hold
500
– – ﹤0.01% 577
2021
Q4 		$22K Buy
+500
New +$28.8K ﹤0.01% 504

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freestone Capital Holdings's IMDX Position: Q2 2023 in Review

Freestone Capital Holdings sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 500 shares — an estimated $3.54K sold.

Freestone Capital Holdings first reported a position in IMDX in Q4 2021 and held it in 6 quarters. The position peaked at $22K in Q4 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

  • Freestone Capital Holdings reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Freestone Capital Holdings sold 500 Insight Molecular Diagnostics shares in Q2 2023, an estimated $3.54K.
  • Freestone Capital Holdings first reported a position in Insight Molecular Diagnostics in Q4 2021 and held it in 6 quarters.
  • Freestone Capital Holdings's Insight Molecular Diagnostics position peaked at $22K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Freestone Capital Holdings's 13F filing for Q2 2023, filed 9 Aug 2023.